Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955135410> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2955135410 endingPage "970" @default.
- W2955135410 startingPage "965" @default.
- W2955135410 abstract "BACKGROUND:Eculizumab is a terminal complement inhibitor used to treat myasthenia gravis in patients refractory (because of insufficient efficacy or intolerance) to other therapies, including intravenous immunoglobulin. However, information is lacking on how to transition patients from intravenous immunoglobulin to eculizumab, while avoiding a crossover effect of intravenous immunoglobulin and minimizing the risk of a transient worsening of symptoms if treatment that may be at least partially effective is interrupted. The aim of this study was to determine whether eculizumab can be safely initiated before complete intravenous immunoglobulin washout, using a standardized protocol. CASE REPORT:A series of 13 patients with generalized treatment-refractory myasthenia gravis were transitioned to eculizumab 10–14 days after their last intravenous immunoglobulin infusion. Patients’ clinical status was assessed before and 6 weeks after transition using the Myasthenia Gravis Composite Score. Most patients (8/13; 62%) had received ≥3 immunosuppressants as well as intravenous immunoglobulin. The median (range) Myasthenia Gravis Composite Score before and 6 weeks after transition was 21 (11–29) and 12 (6–18), respectively. Clinically significant improvements (score decrease ≥3) were observed in all patients. Two patients experienced mild myalgia during transition. CONCLUSIONS:In this case series, patients with treatment-refractory myasthenia gravis were successfully transitioned to eculizumab 10–14 days after their last intravenous immunoglobulin infusion without any significant safety concerns." @default.
- W2955135410 created "2019-07-12" @default.
- W2955135410 creator A5001954609 @default.
- W2955135410 date "2019-07-06" @default.
- W2955135410 modified "2023-09-25" @default.
- W2955135410 title "Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series" @default.
- W2955135410 cites W1646480581 @default.
- W2955135410 cites W1897013744 @default.
- W2955135410 cites W1951143273 @default.
- W2955135410 cites W1971022805 @default.
- W2955135410 cites W1992035277 @default.
- W2955135410 cites W2003039046 @default.
- W2955135410 cites W2004265876 @default.
- W2955135410 cites W2010039737 @default.
- W2955135410 cites W2065357689 @default.
- W2955135410 cites W2069973239 @default.
- W2955135410 cites W2079558011 @default.
- W2955135410 cites W2148590290 @default.
- W2955135410 cites W2151141868 @default.
- W2955135410 cites W2341451501 @default.
- W2955135410 cites W2766784006 @default.
- W2955135410 cites W2776638558 @default.
- W2955135410 cites W2789644345 @default.
- W2955135410 cites W2804781394 @default.
- W2955135410 cites W4230605072 @default.
- W2955135410 doi "https://doi.org/10.12659/ajcr.916424" @default.
- W2955135410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6628751" @default.
- W2955135410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31278249" @default.
- W2955135410 hasPublicationYear "2019" @default.
- W2955135410 type Work @default.
- W2955135410 sameAs 2955135410 @default.
- W2955135410 citedByCount "6" @default.
- W2955135410 countsByYear W29551354102020 @default.
- W2955135410 countsByYear W29551354102021 @default.
- W2955135410 countsByYear W29551354102022 @default.
- W2955135410 crossrefType "journal-article" @default.
- W2955135410 hasAuthorship W2955135410A5001954609 @default.
- W2955135410 hasBestOaLocation W29551354102 @default.
- W2955135410 hasConcept C111684460 @default.
- W2955135410 hasConcept C121332964 @default.
- W2955135410 hasConcept C126322002 @default.
- W2955135410 hasConcept C142424586 @default.
- W2955135410 hasConcept C159654299 @default.
- W2955135410 hasConcept C203014093 @default.
- W2955135410 hasConcept C2777991916 @default.
- W2955135410 hasConcept C2778105408 @default.
- W2955135410 hasConcept C2909916134 @default.
- W2955135410 hasConcept C71924100 @default.
- W2955135410 hasConcept C87355193 @default.
- W2955135410 hasConcept C90924648 @default.
- W2955135410 hasConceptScore W2955135410C111684460 @default.
- W2955135410 hasConceptScore W2955135410C121332964 @default.
- W2955135410 hasConceptScore W2955135410C126322002 @default.
- W2955135410 hasConceptScore W2955135410C142424586 @default.
- W2955135410 hasConceptScore W2955135410C159654299 @default.
- W2955135410 hasConceptScore W2955135410C203014093 @default.
- W2955135410 hasConceptScore W2955135410C2777991916 @default.
- W2955135410 hasConceptScore W2955135410C2778105408 @default.
- W2955135410 hasConceptScore W2955135410C2909916134 @default.
- W2955135410 hasConceptScore W2955135410C71924100 @default.
- W2955135410 hasConceptScore W2955135410C87355193 @default.
- W2955135410 hasConceptScore W2955135410C90924648 @default.
- W2955135410 hasLocation W29551354101 @default.
- W2955135410 hasLocation W29551354102 @default.
- W2955135410 hasLocation W29551354103 @default.
- W2955135410 hasLocation W29551354104 @default.
- W2955135410 hasOpenAccess W2955135410 @default.
- W2955135410 hasPrimaryLocation W29551354101 @default.
- W2955135410 hasRelatedWork W2065357689 @default.
- W2955135410 hasRelatedWork W2324954285 @default.
- W2955135410 hasRelatedWork W2351796763 @default.
- W2955135410 hasRelatedWork W2766097601 @default.
- W2955135410 hasRelatedWork W2766784006 @default.
- W2955135410 hasRelatedWork W2955135410 @default.
- W2955135410 hasRelatedWork W3011996040 @default.
- W2955135410 hasRelatedWork W3040153179 @default.
- W2955135410 hasRelatedWork W3045082024 @default.
- W2955135410 hasRelatedWork W3165199917 @default.
- W2955135410 hasVolume "20" @default.
- W2955135410 isParatext "false" @default.
- W2955135410 isRetracted "false" @default.
- W2955135410 magId "2955135410" @default.
- W2955135410 workType "article" @default.